Eluxadoline: A Review in Diarrhoea-Predominant Irritable Bowel Syndrome

@article{Keating2017EluxadolineAR,
  title={Eluxadoline: A Review in Diarrhoea-Predominant Irritable Bowel Syndrome},
  author={Gillian M. Keating},
  journal={Drugs},
  year={2017},
  volume={77},
  pages={1009-1016}
}
Eluxadoline (Truberzi®) is an orally administered, minimally absorbed agent that acts locally in the gastrointestinal tract as a mixed µ-opioid receptor agonist and δ-opioid receptor antagonist. The randomized, double-blind, placebo-controlled, multinational, phase 3 IBS-3001 and IBS-3002 trials examined the efficacy of eluxadoline in patients with diarrhoea-predominant irritable bowel syndrome (IBS-D). The composite response rate (i.e. the proportion of patients with improvement in both worst… CONTINUE READING